[Federal Register Volume 60, Number 200 (Tuesday, October 17, 1995)]
[Notices]
[Pages 53792-53793]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-25730]



-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

[[Page 53793]]


    The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and a copy of the U.S. patent 
application referenced below may be obtained by contacting Girish C. 
Barua, Ph.D., Technology Licensing Specialist, Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7735 ext 
263; fax 301/402-0220). A signed Confidential Disclosure Agreement will 
be required to receive a copy of the patent application.

Antibacterial Therapy With Bacteriophage Genotypically Modified To 
Delay Inactivation by the Host Defense System

Carlton, R., Merril, C., Adhya, S.
Filed 5 Apr 94
Serial No. 08/222,956

    The present invention is directed to bacteriophage therapy, using 
methods that enable the bacteriophage to delay inactivation by any and 
all parts of the host defense system (HDS) against foreign objects that 
would tend to reduce the numbers of bacteriophage and/or the efficiency 
of those phage at killing the host bacteria in an infection. Disclosed 
is a method of producing bacteriophage modified for anti-HDS purposes, 
one method being selection by serial passaging, and the other method 
being genetic engineering of a bacteriophage, so that the modified 
bacteriophage will remain active in the body for longer periods of time 
than the wild-type phage. [portfolio: Infectious Diseases--
Therapeutics]

    Dated: October 4, 1995.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 95-25730 Filed 10-16-95; 8:45 am]
BILLING CODE 4140-01-P